EP1144458A1 - Substance for reduction of cholesterol as well as lipids content - Google Patents

Substance for reduction of cholesterol as well as lipids content

Info

Publication number
EP1144458A1
EP1144458A1 EP99954018A EP99954018A EP1144458A1 EP 1144458 A1 EP1144458 A1 EP 1144458A1 EP 99954018 A EP99954018 A EP 99954018A EP 99954018 A EP99954018 A EP 99954018A EP 1144458 A1 EP1144458 A1 EP 1144458A1
Authority
EP
European Patent Office
Prior art keywords
substance
microcrystalline chitosan
cholesterol
reduction
lipids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99954018A
Other languages
German (de)
French (fr)
Inventor
Henryk Struszczyk
Harri Pomoell
Marketta Wulff
Elina SÄYNÄTJOKI
Pauli Ylitalo
Erkki Wuolijoki
Harri HÄKLI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novasso Oy
Original Assignee
Novasso Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novasso Oy filed Critical Novasso Oy
Publication of EP1144458A1 publication Critical patent/EP1144458A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the invention relates to a substance for reduction of serum cholesterol as well as lipids content in mammals, especially humans.
  • US-patent 4223023 discloses the use of standard chitosan as a food additive and an orally administrable preparation to reduce the absorption of lipids.
  • microcrystalline chitosan in a form of gel-like dispersion and/or powder characterized by average molecular weight higher than 1 ,000 daltons, preferably 10,000 to 300,000 daltons for reducing cholesterol and higher than 10,000 daltons, preferably 50,000 to 700,000 daltons for reducing lipids, and the deacetylation degree higher than 60 % is described in WO 98/34625.
  • This publication describes the general activity of microcrystalline chitosan for reduction of content of cholesterol and lipids.
  • the object of this invention is to effectively, specially and selectively reduce cholesterol as well as lipids content using microcrystalline chitosan.
  • the substance, in a suitable form to be administered orally is mainly characterized by two fractions of microcrystalline chitosan differing in average molecular weights. These fractions are present simultaneously in the same product which has been prepared by blending the two fractions, each having a characteristic molecular weight distribution and average value of its own.
  • the fraction with lower average molecular weight is responsible for the reduction of cholesterol level, especially the harmful LDL cholesterol, and the fraction with higher average molecular weight incorporated in the same formulation is responsible for the reduction of lipids. It is also possible that the fractions differ in other properties as well.
  • the microcrystalline chitosan in the product is combined with synergistic active substances to increase the cholesterol and lipids reduction.
  • microcrystalline chitosan present in at least two fractions is in a form of powder and/or gel-like dispersion and it is combined with synergistic active substances such as organic acids like ascorbic acid and/or carbonates like sodium carbonate, calcium carbonate and/or magnesium carbonate to improve the efficiency of substance in the body and to increase the cholesterol and lipids reduction.
  • synergistic active substances such as organic acids like ascorbic acid and/or carbonates like sodium carbonate, calcium carbonate and/or magnesium carbonate to improve the efficiency of substance in the body and to increase the cholesterol and lipids reduction.
  • microcrystalline chitosan is combined with synergistic active substances in a weight ratio ranged from 1 :0.001 to 0.001 :1 , preferably 1 :0.01 to 0.01 :1.
  • the polydispersity of the blended selected polymer fractions is lower than 4.0.
  • the first fraction has average molecular weight below 140 kD, preferably ranging from 20 to 140 kD for reduction of cholesterol content.
  • the second fraction has average molecular weight higher than 140 kD, preferably in the range of 160-400 kD and most preferably in the range of 200-400 kD for reduction of lipids content and is thus responsible for slimming effect.
  • the weight ratio of the two microcrystalline chitosan fractions ranges from 1 :99999 to 99999:1 , preferably from 1 :4999 to 4999:1.
  • the most practical embodiments have the ratios between 1:19 and 19:1 , preferably between 1 :9 and 9:1.
  • microcrystalline chitosan is combined with additives characterized by high synergistic action with this natural polymeric material that is able to form complexes with cholesterol and lipids.
  • the synergistic additives consisting of organic acids like ascorbic acid and/or suitable carbonates like sodium carbonate, calcium carbonate and/or magnesium carbonate in a presence of microcrystalline chitosan improve the special form of chitosan activity, protect the mammal organism system as well as protect against removal of the fat-soluble vitamins A and E.
  • Microcrystalline chitosan has a highly developed intrinsic surface, high positive charge and good ability to create hydrogen and ionic bonds and can form a complex with the synergistic active substances.
  • the carbonates contribute to the advantageous behaviour of the administered preparation in the gastrointestinal tract and keep the microcrystalline chitosan well dispersed in the stomach by releasing carbon dioxide upon contact with the acidic environment of the stomach. Further, by suitably choosing the balance between the various carbonates the pH of the preparation can be adjusted.
  • the selectivity of the rate of microcrystalline chitosan action for reduction of cholesterol and/or lipids according to the invention is connected with its fractional content as well as polydispersity degree lower than 4.0.
  • the first fraction of microcrystalline chitosan defined with viscometric average molecular weight as lying below 140 kD, preferably in a range of 20-140 kD, is subjected to faster enzymatic degradation producing suitable amount of oligoaminosaccharides with assumed structure and ability to combine at high rate with cholesterol, especially its low density fraction LDL (low density lipoprotein).
  • the second fraction of microcrystalline chitosan defined with viscometric average molecular weight to lie higher than 140 kD, preferably from 160 to 400 kD and most preferably in a range of 200-400 kD, is responsible for reduction of lipids content. Suitable ratio of above fractions in the microcrystalline chitosan used makes possible the selective, specific action against cholesterol on one hand and lipids on the other hand.
  • the substance according to the invention containing microcrystalline chitosan after 4 weeks of patient treatment has reduced the total cholesterol content more than 6 % and the LDL cholesterol more than 15 % in comparison to the initial levels.
  • the advantage of substance containing microcrystalline chitosan is connected with its variety of possible forms from powder to gel-like dispersion. It is not necessary to use a special diet together with the substance according to the invention.
  • the essential components of the substance can be included in an orally administrable unit together with a pharmaceutically accepetable carrier.
  • the substance can thus be in the form of a capsule, tablet or pill.
  • microcrystalline chitosan properties viscometric average molecular weight according to the method described in "Chitin”, Pergamon Press, Oxford, 1977 - deacetylation degree according to the method described in the “Cellulose Chemistry and Technology", vol. 11 , p. 633, 1977 polydispersity as well as fraction content according to the Gel Permeation Chromatography method.
  • 51 healthy females with body mass index ranging from 28.0 to 34.99 were subjected to in vivo test conducted according to the Declaration of Helsinki and Tokyo with trial plan reviewed by the local ethics committee. The trial was also conducted according to the Good Clinical Practice rules. The patients were asked to maintain their daily living routines including eating habits.
  • the identical capsules containing starch as placebo were used for comparison.
  • the procedure produced a daily dose of 2.4 g of microcrystalline chitosan to be taken in three capsules twice a day.
  • the same system was used for placebo.
  • microcrystalline chitosan powder characterized by viscometric average molecular weight of 300 kD, deacetylation degree of 84.7 % and polydispersity degree of 3.42 was blended with 99.9 weight parts of fraction of microcrystalline chitosan characterized by viscometric average molecular weight of 123 kD, deacetylation degree of 84.8. % and polydispersity degree of 3.67.
  • the blended microcrystalline chitosan powder was characterized by viscometric average molecular weight of 122 kD, deacetylation degree of 84,8 % and polydispersity degree of 3.65.
  • Example 3 400 mg of above blend with addition of 70 mg of active synergistic agents as in Example 1 were used in a form of capsules for reduction of cholesterol and lipids content. The procedure was as in Example 1. The patient characteristics as well as results of treatment after 8 weeks are presented in Table 3.
  • Vitamin A ( ⁇ M/l) before 2.44 ⁇ 0.4 2.31 ⁇ 0.3 after 2.41 ⁇ 0.3 2.29 ⁇ 0.3
  • Vitamin E ( ⁇ M/l) before 24.80 ⁇ 5.4 24.00 ⁇ 3.8 after 24.60 ⁇ 5.4 24.91 ⁇ 4.1
  • Raising the average molecular weight will result in still more lipids being absorbed, in the range 75 to 87 %, and the optimal range of Mw is between 200 and 400 kD.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

The invention relates to a substance for reduction of cholesterol as well as lipids content based on the microcrystalline chitosan in a form of solid or gel-like dispersion. The microcrystalline chitosan in a form of powder and/or gel-like dispersion contains a blend of two fractions having differing molecular weights, one reducing the cholesterol (LDL) content and the other reducing the lipids content. The microcrystalline chitosan is further combined with synergistic active substances such as organic acids like ascorbic acid and/or carbonates like sodium carbonate, calcium carbonate and/or magnesium carbonate to increase the cholesterol and lipids reduction.

Description

Substance for reduction of cholesterol as well as lipids content
The invention relates to a substance for reduction of serum cholesterol as well as lipids content in mammals, especially humans.
The problem caused by lipids and chloesterol to human health are known, such as overweight problems and cardiovascular diseases. Many attempts have been made to reduce the negative effect of lipids and cholesterol contained in the food. One alternative is a special low- fat or fat-free diet. Another solution has been the administration of special drugs or use of special food additives.
US-patent 4223023 discloses the use of standard chitosan as a food additive and an orally administrable preparation to reduce the absorption of lipids.
The reduction of lipids and cholesterol by microcrystalline chitosan in a form of gel-like dispersion and/or powder characterized by average molecular weight higher than 1 ,000 daltons, preferably 10,000 to 300,000 daltons for reducing cholesterol and higher than 10,000 daltons, preferably 50,000 to 700,000 daltons for reducing lipids, and the deacetylation degree higher than 60 % is described in WO 98/34625. This publication describes the general activity of microcrystalline chitosan for reduction of content of cholesterol and lipids.
All well-known slimming or cholesterol reducing agents based on chitosan are non-selective for their activity as well as efficiency of action.
The object of this invention is to effectively, specially and selectively reduce cholesterol as well as lipids content using microcrystalline chitosan. For achieving the objects the substance, in a suitable form to be administered orally, is mainly characterized by two fractions of microcrystalline chitosan differing in average molecular weights. These fractions are present simultaneously in the same product which has been prepared by blending the two fractions, each having a characteristic molecular weight distribution and average value of its own. The fraction with lower average molecular weight is responsible for the reduction of cholesterol level, especially the harmful LDL cholesterol, and the fraction with higher average molecular weight incorporated in the same formulation is responsible for the reduction of lipids. It is also possible that the fractions differ in other properties as well. According to an advantageous embodiment the microcrystalline chitosan in the product is combined with synergistic active substances to increase the cholesterol and lipids reduction.
The microcrystalline chitosan present in at least two fractions is in a form of powder and/or gel-like dispersion and it is combined with synergistic active substances such as organic acids like ascorbic acid and/or carbonates like sodium carbonate, calcium carbonate and/or magnesium carbonate to improve the efficiency of substance in the body and to increase the cholesterol and lipids reduction.
According to a preferred embodiment of the invention the microcrystalline chitosan is combined with synergistic active substances in a weight ratio ranged from 1 :0.001 to 0.001 :1 , preferably 1 :0.01 to 0.01 :1.
According to a preferred embodiment of the invention the polydispersity of the blended selected polymer fractions is lower than 4.0. The first fraction has average molecular weight below 140 kD, preferably ranging from 20 to 140 kD for reduction of cholesterol content. The second fraction has average molecular weight higher than 140 kD, preferably in the range of 160-400 kD and most preferably in the range of 200-400 kD for reduction of lipids content and is thus responsible for slimming effect. The weight ratio of the two microcrystalline chitosan fractions ranges from 1 :99999 to 99999:1 , preferably from 1 :4999 to 4999:1. The most practical embodiments have the ratios between 1:19 and 19:1 , preferably between 1 :9 and 9:1.
The microcrystalline chitosan is combined with additives characterized by high synergistic action with this natural polymeric material that is able to form complexes with cholesterol and lipids. The synergistic additives consisting of organic acids like ascorbic acid and/or suitable carbonates like sodium carbonate, calcium carbonate and/or magnesium carbonate in a presence of microcrystalline chitosan improve the special form of chitosan activity, protect the mammal organism system as well as protect against removal of the fat-soluble vitamins A and E. Microcrystalline chitosan has a highly developed intrinsic surface, high positive charge and good ability to create hydrogen and ionic bonds and can form a complex with the synergistic active substances. The carbonates contribute to the advantageous behaviour of the administered preparation in the gastrointestinal tract and keep the microcrystalline chitosan well dispersed in the stomach by releasing carbon dioxide upon contact with the acidic environment of the stomach. Further, by suitably choosing the balance between the various carbonates the pH of the preparation can be adjusted.
The selectivity of the rate of microcrystalline chitosan action for reduction of cholesterol and/or lipids according to the invention is connected with its fractional content as well as polydispersity degree lower than 4.0. The first fraction of microcrystalline chitosan, defined with viscometric average molecular weight as lying below 140 kD, preferably in a range of 20-140 kD, is subjected to faster enzymatic degradation producing suitable amount of oligoaminosaccharides with assumed structure and ability to combine at high rate with cholesterol, especially its low density fraction LDL (low density lipoprotein). The second fraction of microcrystalline chitosan, defined with viscometric average molecular weight to lie higher than 140 kD, preferably from 160 to 400 kD and most preferably in a range of 200-400 kD, is responsible for reduction of lipids content. Suitable ratio of above fractions in the microcrystalline chitosan used makes possible the selective, specific action against cholesterol on one hand and lipids on the other hand.
The substance according to the invention containing microcrystalline chitosan after 4 weeks of patient treatment has reduced the total cholesterol content more than 6 % and the LDL cholesterol more than 15 % in comparison to the initial levels. The advantage of substance containing microcrystalline chitosan is connected with its variety of possible forms from powder to gel-like dispersion. It is not necessary to use a special diet together with the substance according to the invention.
The essential components of the substance can be included in an orally administrable unit together with a pharmaceutically accepetable carrier. The substance can thus be in the form of a capsule, tablet or pill.
The following methods were used for the determination of microcrystalline chitosan properties: viscometric average molecular weight according to the method described in "Chitin", Pergamon Press, Oxford, 1977 - deacetylation degree according to the method described in the "Cellulose Chemistry and Technology", vol. 11 , p. 633, 1977 polydispersity as well as fraction content according to the Gel Permeation Chromatography method.
The contents of total cholesterol, LDL as well as HDL cholesterol triglycerides as well as vitamin A and E were determined according to the standards.
The invention is explained further in the following examples which do not restrict the scope of claims.
Example 1.
The capsules based on hard gelatin with 400 mg of microcrystalline chitosan powder characterized by viscometric average molecular weight of 137 kD, deacetylation degree of 76 % and polydispersity degree of 3.84 and 70 mg of active synergistic agent including 3.8 mg of ascorbic acid, 18.8 mg of sodium carbonate, 25.8 mg of calcium carbonate and 21.6 mg of magnesium carbonate were used for reduction of cholesterol and lipids content. 51 healthy females with body mass index ranging from 28.0 to 34.99 were subjected to in vivo test conducted according to the Declaration of Helsinki and Tokyo with trial plan reviewed by the local ethics committee. The trial was also conducted according to the Good Clinical Practice rules. The patients were asked to maintain their daily living routines including eating habits. The identical capsules containing starch as placebo were used for comparison. The procedure produced a daily dose of 2.4 g of microcrystalline chitosan to be taken in three capsules twice a day. The same system was used for placebo. The patient characteristic is presented in Table 1.
Table 1. Patients characteristic before treatment (data given as means ± SD)
Patient Treatment group
Chitosan/range Placebo/range Totals
Number 24 27 51
Age (year) 41.4 ± 7.8 / 24-57 41.3 ± 7.1 / 19-55 41.3 ± 7.3
Height (cm) 165.1 165.2 165.1
Weight (kg) 83.33 ± 9.2 / 71-105 84.63 ± 7.8 / 71 -101 84 ± 8.4
Body mass index 30.39 ± 2.1 / 28-35 30.81 ± 2.2 / 28-35 30.61 ± 2 fs-chol.tot. (mmol/l) 5.55 ± 0.9 5.48 ± 0.8 5.51 ± 0.9 fs-HDL (mmol l) 1.33 ± 0.3 1.34 ± 0.4 1.37 ± 0.4 fs-Trigl. (mmol/l) 1.24 ± 0.6 1.40 ± 0.6 1.33 ± 0.6 fs-LDL (mmol/l) 3.65 ± 0.9 3.45 ± 0.7 3.55 ± 0.8
The treatment parameters after 4 weeks are presented in Table 2. Table 2. Treatment parameters after 4 weeks
Parameter Chitosan Placebo
Number of patients 24 27 fs-chol.tot. (mmol/l) 5.23 + 0.8 5.41 + 0.8 difference - 0.32 - 0.07 fs-HDL (mmol/l) 1.48 + 0.4 1.54 + 0.5 difference + 0.15 + 0.14 fs-LDL (mmol/l) 3.18 ± 0.8 3.27 ± 0.7 difference - 0.47 - 0.18 fs-Trigl. (mmol/l) 1.26 + 0.6 1.34 + 0.8 difference + 0.2 - 0.06
As the result of 4 weeks long test the serum mean total cholesterol decreased for the patients treated by microcrystalline chitosan by 0.32 mmol/l, whereas with the placebo group only by 0.07 mmol/l. The low density cholesterol (LDL) for microcrystalline chitosan treated group was reduced by 0.48 mmol/l, whereas for the placebo group by 0.18 mmol/l only.
Example 2.
0.1 weight parts of microcrystalline chitosan powder characterized by viscometric average molecular weight of 300 kD, deacetylation degree of 84.7 % and polydispersity degree of 3.42 was blended with 99.9 weight parts of fraction of microcrystalline chitosan characterized by viscometric average molecular weight of 123 kD, deacetylation degree of 84.8. % and polydispersity degree of 3.67. The blended microcrystalline chitosan powder was characterized by viscometric average molecular weight of 122 kD, deacetylation degree of 84,8 % and polydispersity degree of 3.65. 400 mg of above blend with addition of 70 mg of active synergistic agents as in Example 1 were used in a form of capsules for reduction of cholesterol and lipids content. The procedure was as in Example 1. The patient characteristics as well as results of treatment after 8 weeks are presented in Table 3.
Table 3. The patient characteristics and treatment parameters after 8 weeks
Parameter Chitosan Placebo
before after before after
Number of patients 11 11 14 14
Age, years 38 ± 8 - 44 ± 5 -
Height, cm 165 ± 7 - 165 ± 6 -
Body mass index 32 ± 2 32 ± 2 33 ± 2 33 ± 2 fs-chol.tot. (mmol/l) 5.75 ± 1.0 5.37 ± 0.9 5.41 ± 0.6 5.19 ± 0.8 difference - - 0.38 - - 0.22 fs-HDL (mmol/l) 1.43 ± 0.29 1.45 ± 0.32 1.27 ± 0.43 1.36 ± 0.51 difference - + 0.02 - + 0.09 fs-LDL (mmol/l) 3.79 ± 0.94 3.49 ± 0.64 3.31 ± 0.82 3.23 ± 0.79 difference - - 0.30 - - 0.08 fs-Trigl. (mmol/l) 1.20 ± 0.45 1.40 ± 0.39 1.33 ± 0.49 1.33 ± 0.43 difference - + 0.2 - 0
As the result of 8 weeks long test, the serum total cholesterol decreased for the patients treated with microcrystalline chitosan by 0.38 mmol/l whereas with the placebo group only by 0.22 mmol/l. The low density cholesterol of LDL for the first group decreased by 0.30 mmol/l whereas for the second group by 0.08 mmol/l only. At the same time the fat soluble vitamins A and E were analyzed before trial as well as after 8 weeks of trial. The results of this test are presented in Table 4.
Table 4. The fat soluble vitamins A and E Type of vitamins Chitosan treatment Placebo treatment
Vitamin A (μM/l) before 2.44 ± 0.4 2.31 ± 0.3 after 2.41 ± 0.3 2.29 ± 0.3
Vitamin E (μM/l) before 24.80 ± 5.4 24.00 ± 3.8 after 24.60 ± 5.4 24.91 ± 4.1
The results of fat soluble vitamin tests confirm that the used microcrystalline chitosan is fully safe as for their contents.
Example 3.
Several samples of microcrystalline chitosan (MCCh) powder with a dry weight of 0.15 g and with similar deacetylation degree of DD = 80- 85 %, characterized by viscometric average molecular weight in a range of Mw = 20-180 kD as well as the MCCh formulation with composition presented in Example 1 with viscometric average molecular weight of 130 kD and with a dry MCCh weight of 0.15 g, and a commercially available "fat blocker" containing standard chitosan with DD = 74 % and Mw = 125 kD were used for a test of the fat binding effectivity according to the modified method described by S. Demarger- Andre and A. Domard in Carbohydrate Polymers 22 (1993) 117-126.
The fat binding effectivity calculated as the percentage of total fat bound in comparison to initial fatty acids, is presented in following Table 5. Table 5. Fat binding effectivity for different chitosan forms
Type of chitosan Mw Fatty acids binding effectivity kD %
MCCh 20 44.4
MCCh 165 54.2
MCCh 145 57.0
MCCh 180 52.6
MCCh formulation 130 31.8
Commercial "fat blocker" with 125 17.6 standard chitosan
The presented results of the test show that the total fat binding effectivity expresses the action of the MCCh in relation to its average molecular weight. MCCh formulation with composition as in Example 1 has presented the total fat binding effectivity higher than 81 %, in comparison to the commercially available "fat blocker" containing standard chitosan.
Raising the average molecular weight will result in still more lipids being absorbed, in the range 75 to 87 %, and the optimal range of Mw is between 200 and 400 kD.

Claims

Claims:
1. Substance for reduction of cholesterol as well as lipids content based on the microcrystalline chitosan in a form of solid or gel-like dispersion, characterized in that the microcrystalline chitosan used in a form of powder and/or gel-like dispersion contains a blend of at least two fractions having differing average molecular weights.
2. Substance as claimed in claim 1 , characterized in that the blended selected polymer fractions have a polydispersity degree lower than 4.0.
3. Substance as claimed in claim 1 or 2, characterized in that the first fraction has average molecular weight below 140 kD, preferably ranging from 20 to 140 kD, to create the reduction of cholesterol content, and the second fraction has average molecular weight above 140 kD, preferably between 160 and 400 kD and most preferably in a range of 200-400 kD to reduce lipids content responsible for slimming effect.
4. Substance as claimed in any of claims 1 to 3, characterized in that the microcrystalline chitosan in a form of powder and/or gel-like dispersion is combined with synergistic active substances such as organic acids like ascorbic acid and/or carbonates like sodium carbonate, calcium carbonate and/or magnesium carbonate to increase the cholesterol and lipids reduction.
5. Substance as claimed in claim 4, characterized in that the microcrystalline chitosan is combined with sodium carbonate, calcium carbonate and magnesium carbonate.
6. Substance as claimed in any of claims 1 to 5, characterized in that the weight ratio of the two microcrystalline chitosan fractions ranges from 1 :99999 to 99999:1.
7. Substance as claimed in claim 6, characterized in that the weight ratio of the two microcrystalline chitosan fractions ranges from 1 :4999 to 4999:1.
8. Substance as claimed in claim 7, characterized in that the weight ratio of the two microcrystalline chitosan fractions ranges from 1 :19 to 19:1 , preferably from 1 :9 to 9:1.
9. Substance as claimed in any of the preceding claims, characterized in that the microcrystalline chitosan is combined with synergistic active substance in a weight ration ranging from 1 :0.001 to 0.001 :1 , preferably 1 :0.01 to 0.01 :1.
10. Substance as claimed in any of the preceding claims, characterized in that it is in form of an orally administrable capsule, tablet or pill.
EP99954018A 1998-10-23 1999-10-25 Substance for reduction of cholesterol as well as lipids content Withdrawn EP1144458A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI982291 1998-10-23
FI982291A FI982291A (en) 1998-10-23 1998-10-23 An agent for lowering cholesterol and lipids
PCT/FI1999/000885 WO2000024785A1 (en) 1998-10-23 1999-10-25 Substance for reduction of cholesterol as well as lipids content

Publications (1)

Publication Number Publication Date
EP1144458A1 true EP1144458A1 (en) 2001-10-17

Family

ID=8552763

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99954018A Withdrawn EP1144458A1 (en) 1998-10-23 1999-10-25 Substance for reduction of cholesterol as well as lipids content

Country Status (7)

Country Link
EP (1) EP1144458A1 (en)
JP (1) JP2002528571A (en)
CN (1) CN1331703A (en)
AU (1) AU1048600A (en)
CA (1) CA2347967A1 (en)
FI (1) FI982291A (en)
WO (1) WO2000024785A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE522529C2 (en) * 2001-04-12 2004-02-17 Medicarb Ab Effervescent solid composition used for treating dermal wounds comprises chitosan or component releasing carbon dioxide in acidic environment
CA2443471A1 (en) * 2001-04-12 2002-10-24 Medicarb Ab An effervescent solid composition of matter
KR100473445B1 (en) * 2001-05-10 2005-03-08 씨제이 주식회사 cholesterol reducer and health food containing chitosan and ε-polylysine
ES2209632B1 (en) * 2002-08-30 2005-08-01 Romildo Holding, N.V. DIETETIC, SOLUBLE, EFFECTIVE AND FOOD COMPLEMENT.
US20060058261A1 (en) * 2004-09-15 2006-03-16 Andre Aube Chitin derivatives for hyperlipidemia
EP1960436A1 (en) * 2005-12-16 2008-08-27 Dnp Canada Inc. Chitin derivatives for hyperlipidemia
US9000149B2 (en) * 2006-12-07 2015-04-07 Ben-Bar Technology 2006 Ltd. Mixture and method for reducing cholesterol using hydrophobic microparticles
EP2016946B1 (en) * 2007-07-18 2013-02-27 The Jordanian Pharmaceutical Manufacturing Co. Chitosan silicon dioxide coprecipitate composition for use as a therapeutically active agent
CN102469782A (en) 2010-06-18 2012-05-23 哈洛资源公司 Formulations and methods for solid chitosan-containing blends
CN102504291B (en) * 2011-10-28 2014-01-01 北京联合大学生物化学工程学院 pH sensitive type chitosan crosslinking povidone gel and preparation method and application thereof
CN115568321B (en) * 2022-09-16 2024-04-02 江苏省农业科学院 Method for prolonging physiological function period of leaf of Su Cui No. 1 pear

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223023A (en) * 1978-10-12 1980-09-16 Ivan Furda Nonabsorbable lipid binder
FI83426C (en) * 1989-06-30 1991-07-10 Firextra Oy FOERFARANDE FOER KONTINUERLIG FRAMSTAELLNING AV MICROCRYSTALLINE KITOSAN.
JPH07100040B2 (en) * 1992-11-24 1995-11-01 朝日食品工業株式会社 Method for measuring molecular weight distribution of chitosan and / or partially decomposed product thereof
FI107432B (en) * 1997-02-06 2001-08-15 Novasso Oy Use of microcrystalline chitosan

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0024785A1 *

Also Published As

Publication number Publication date
FI982291A (en) 2000-04-24
AU1048600A (en) 2000-05-15
FI982291A0 (en) 1998-10-23
WO2000024785A1 (en) 2000-05-04
CN1331703A (en) 2002-01-16
CA2347967A1 (en) 2000-05-04
JP2002528571A (en) 2002-09-03

Similar Documents

Publication Publication Date Title
JP2667351B2 (en) Dietary lipid digestion and absorption inhibitors and foods and beverages
US5262167A (en) Edible, non-baked low moisture cholestyramine composition
EP1679009B1 (en) Pharmaceutical and dietetic compositions based on vegetable fibres
WO2000024785A1 (en) Substance for reduction of cholesterol as well as lipids content
CA1094451A (en) Method of controlling fecal output and compositions therefor
JP2015516372A (en) Compositions and methods for enhancing antioxidants, enteric flora and immunity in pets
TR201810187T4 (en) Composition for reducing dietary fat absorption.
Bordoni et al. The role of bioactives in energy metabolism and metabolic syndrome
Burton et al. Influence of a psyllium‐based fibre preparation on faecal and serum parameters
US20100215687A1 (en) Soluble Fiber Combinations for Weight Control and Improving Parameters of Cardiovascular Health
Schaus et al. Bioavailability of vitamin E in rats fed graded levels of pectin
US6703419B1 (en) Chemical composition for aiding the absorption, binding and elimination of undigested fat
WO2000010586A1 (en) Composition and method for eliminating undigested fat and reducing cholesterol in the human body
US20070167395A1 (en) Compositions and methods for treating diabetes
FI107432B (en) Use of microcrystalline chitosan
Lipsky et al. Dietary fiber for reducing blood cholesterol
US5773427A (en) Prevention of fiber-induced intestinal gas production by chitosan
US6200574B1 (en) Chemical composition for aiding the absorption, binding and elimination of undigested fat
KR20010103065A (en) Diet composition comprising dietary fiber
US6506420B2 (en) Combinations of psyllium and chitosan for synergistic adsorption of triglyceride
Preuss et al. Chitosan as a dietary supplement for weight loss: a review
KR20190035623A (en) Edible compositions for reducing the digestion or absorption of harmful / toxic substances
Abdalla et al. Evaluation Anti-Obesity Activity of Psyllium Seeds Powder on Rats Fed a High Fat Diet
WO2022169889A1 (en) Encapsulated compositions and method of use - affecting satiety
EP2016946A1 (en) Chitosan silicon dioxide coprecipitate composition for use as a therapeutically active agent

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010523

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030502